Actively Recruiting
Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation.
Led by Hospital JP Garrahan · Updated on 2025-04-16
500
Participants Needed
1
Research Sites
786 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This trial proposes a therapy for pediatric Hodgkin lymphoma with the objective of achieving high levels of long lasting complete remission with less risk of late effects. Patients of both genders, between 2 and 18 years, with newly diagnosed classical Hodgkin lymphoma are admitted. Initial staging provides stratification in three groups: low, intermediate and high risk. An initial set of two chemotherapy courses is administered to all cases after which a new disease assessment is performed. According to disease response a final therapy group is assigned. Rapid early responders benefit from less chemotherapy. At the end of chemotherapy, radiotherapy is delivered only to patients who do not achieve a complete response. Thus therapy is tailored to initial extension and disease responsiveness. Complete responders at the end of chemotherapy do not receive radiotherapy. Those who are in partial remission receive low dose (30Gy) involved node radiotherapy. Stable or progressive disease at any moment is assumed as a trial failure and new therapeutic strategies are offered to patients off protocol. Chemotherapy is based upon regimes with well known effectiveness in Hodgkin lymphoma. (i.e. ABVD: doxorubicin, bleomycin, vinblastine and dacarbazine and ESHAP: Etoposide, methyl prednisolone, citarabine and cisplatin). The schedules are delivered with low cumulative drug doses and avoiding the use of toxic alkylating agents. Risks of secondary leukemia and infertility are thus minimized. Doxorubicin and bleomycin do not achieve cumulative doses that may expose to significant risk of heart or lung damage. Radiotherapy reduction avoids late radiation sequels. This clinical study proposes a therapeutic approach based on chemotherapy that do not sum up high cumulative toxic doses. Therapy is tailored according to initial risk assessment and disease responsiveness. Those who achieve a complete response to chemotherapy do not receive additional radiotherapy, thus avoiding further late effects.
CONDITIONS
Official Title
Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histopathological diagnosis of classical Hodgkin lymphoma.
- Normal renal, hepatic, pulmonary and metabolic function standards.
- Informed consent signed by patient and/or legal caretakers.
You will not qualify if you...
- Lymphocyte predominant nodular Hodgkin lymphoma.
- Any form of immunodeficiency before diagnosis, including primary immunodeficiencies, transplant recipients, or immunosuppressive therapies within 28 days before diagnosis.
- Pregnancy or breastfeeding.
- Sexually active females not using effective contraception during therapy.
- Positive HIV serology.
- Penfigus or hepatic ductopenia.
- Hodgkin lymphoma as a secondary malignant disease.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hospital JP Garrahan
Buenos Aires, Buenos Aires F.D., Argentina, C1245AAL
Actively Recruiting
Research Team
P
Pedro A Zubizarreta, MD
CONTACT
E
Elizabeth M Alfaro, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
7
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here